Phase I clinical trial - VADS
TG4050.02
VADS
Essai clinique fermé
Public cible
Adulte
A randomized phase I trial in patients with newly-diagnosed, locoregionally advanced, HPV-negative, squamous cell carcinoma of the head and neck (SCCHN);evaluating a mutanome-directed immunotherapy;initiated at completion of primary treatment or at time of recurrence
Description de l'essai
To evaluate the safety and tolerability of multiple subcutaneous injections of a mutanome-directed active immunotherapy (TG4050) in patients with newly diagnosed, locoregionally advanced, HPV-negative SCCHN initiated at completion of primary treatment (Arm A) or at the time of recurrence (Arm B)
Liens utiles
